ERBB2 and neoplasm: Overexpression driven by gene amplification correlates with a more aggressive tumor phenotype, increased recurrence risk, and historically poorer outcomes (2–7) — a reality mitigated by the advent of HER2-targeted therapies, which have transformed early-stage HER2-positive BC into a highly curable disease and significantly improved survival in the metastatic context (2).